Statement by Mr. Nicolas Sarkozy, President of the Republic, on the fight against Alzheimer's disease, in Paris on September 21, 2007.

France Nicolas Sarkozy · President of France

21 September 2007 · World Alzheimer's Day · City of Science and Industry, Paris, France

Context
Sarkozy addressed patients, families, and experts on World Alzheimer's Day at the City of Science and Industry in Paris to announce France's national Alzheimer's Plan.
Main themes
Alzheimer's disease, national Alzheimer's plan 2008–2012, research and treatment, patient-centered care, caregiver support, funding and resources, public health policy, scientific progress, ethical dimension of care, family support, government commitment
Duration
~26 min
77th percentile
Words
3,158
77th percentile
Sentences
203
89th percentile
Readability
57
80th percentile
Grade
9.2
13th percentile
Syntax
2.76
18th percentile
Vocabulary
2.10
27th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 65%65%
  • Institutional 17%17%
  • Ceremonial 9%9%
  • Economic 4%4%
  • Technological 4%4%
  • Geopolitical 0%0%
  • Environmental 0%0%
  • Not in focus 1%

203 sentences in 18 paragraphs

Madam President,

Ladies and gentlemen ministers,

Ladies and gentlemen,

I am pleased to be with you today, on this World Alzheimer’s Day, at the City of Science and Industry. I am happy to speak before patients, families, caregivers, professionals, experts, and all those who live with the disease every day, all those who are engaged in this formidable battle against Alzheimer’s disease.

First, I want to greet you, Madam President, and commend the work of your association. The work you do on the ground is exemplary. Your enthusiasm and dynamism are a precious support for the 850,000 patients and their families. In the face of the suffering of families, France Alzheimer is the foremost caregiver. You know in detail the many shortcomings in the care of this disease. You are the indispensable driving force in the fight against Alzheimer’s disease. Thank you for that. Your work is just, and it will be supported by the State.

I would like to remind you of the timeline for the development of the Plan. I established the commission chaired by Professor Joël MENARD, whom I want to thank, on September 3rd. In the mission letter I sent him, I asked the Professor to provide me with the first orientations of the Alzheimer Plan by September 21st. About a hundred experts from various disciplines have been working for the commission since August. Some of them are here. After several weeks of work, key lines are emerging. I have come to present them to you today. The commission's mission, of course, is not finished. It will submit its final proposals at the beginning of November. I am happy to find a place in France where people think I am not doing enough and, above all, not fast enough. I am well aware that the expectations are immense and that we do not have time. Then, after the submission of the final proposals in November, there will be a public debate organized by Roselyne BACHELOT, Xavier BERTRAND, Valérie PECRESSE, and Valérie LETARD. We will hold this debate on the content of the Alzheimer Plan. We will involve all the professionals in the field in this debate. But we will also involve, beyond that, all the French people, because this disease, unfortunately, can affect all French people. The Alzheimer Plan is a large-scale project, spanning 5 years, from 2008 to 2012. I have asked the Prime Minister to oversee its implementation, with the ongoing involvement of the four ministers who are here, whom I want to greet and thank. There will be resources funded, notably, by the franchises. Ladies and gentlemen, I am not simply going to tell you: we need to spend more. I have explained to the French people that we need more resources. It is all well and good to say that we need to spend more, but the credibility of those who promise more resources depends on their ability to commit to the resources. It is not so easy to explain the franchise, to propose it to the French people, and to get it through, dear Roselyne. That is what we have done. I have not hidden. I have said that in the face of the challenge of Alzheimer’s, the challenge of cancer, the challenge of palliative care, the challenge of hospitals, we need these additional resources. It is easier to announce additional means than additional resources. But who here could believe me if I announced additional means without a way to obtain them in a country that has so many deficits? This country, of course, is ours. In 2011, after 3 years of implementation, we will conduct a public evaluation of the plan and thus of its results. Madam President, I wanted, as you can see, a sustained tempo. I have not left much time for the professors to work. But if I have done this, it is not a matter of temperament, as I see written so lightly. If it were only my temperament, we would have gone even faster! It is a matter of urgency, because I could not see myself explaining that, in the face of the tragedy of Alzheimer’s, we remained idle. There are already 850,000 families. What more are we going to wait for? We do not have time to wait. I want to thank all the members of the Commission around you, Mr. President, for the work you have already begun.

The first proposed orientation reminds us that the Alzheimer Plan has an ethical dimension. Between the discovery of symptoms in Germany in 1906 and today, what do we know more? Our knowledge of the disease has progressed, particularly thanks to the dynamism of a number of French teams, which I want to acknowledge here. But we still do not know its mechanisms. Ultimately, I regret to note that we are still at the beginning of the story of this disease. That is why we must put all our strength into understanding this disease. We must accelerate the story to discover a treatment and a diagnosis. By placing the sick person at the heart of our action. The scientific advances that the Alzheimer Plan will stimulate must never make us lose sight of the fact that what is most important is the person who suffers. It is the patient who endures, who waits. The patient is not an object of research or science who knows nothing of the purpose of the research. They are a full human being, who must be treated as such, with respect for their dignity. I want to break the unjustified link between age and memory loss and behavioral disorders. Old age is not a disease.

An elderly person who is well advised and well cared for retains their senses and activities, unless they have, as at all other ages, an illness. It is too easy to say that because one is old, it is normal to be sick and therefore it is normal to lose one’s dignity. The definition of age by administrative thresholds, 60, 65, 70 years - I did not mention 50, I feel concerned - creates arbitrary discrimination for both sides. We must personalize medical and social assistance, based on the past and environment of the patient: medications, care, social support, home help, respite for caregivers. This is national solidarity, to which we must add family solidarity or insurance that must also finance this assistance, beyond what each person's personal responsibility can bear. I want ethical reflection to be more widespread. Scientific knowledge will evolve and our view of loss of autonomy will change. Ethical reflection on people suffering from Alzheimer’s disease must be permanent and no longer intermittent. It must be known and no longer confidential. This reflection will have funding within the framework of the Alzheimer Plan. I hope it will serve to improve the journey of patients, to keep them within the family and social fabric, to strengthen the links between care and research. The question of announcing the disease is crucial. Should we not foresee, as is done when cancer is discovered, a better articulated announcement system that is also more respectful of individuals? Patients need research, but research needs patients. Beyond words, the integration of care and research will be improved if the information provided to patients about research is complete. I expect concrete proposals from the commission so that ethical reflection has direct repercussions on the fate of patients.

The second orientation suggested by the commission concerns, precisely Valérie, research. Research, that is the great forgotten aspect of previous plans. Without a validated diagnostic test, without treatment, there can be no stopping the progression of the disease. I have said that French researchers have advanced the understanding of the disease. It involves a small number of teams. This is insufficient in the face of the stakes of the disease. It is insufficient in the 21st century, the century of the brain. French neuroscience is brilliant, but does it meet all the challenges? In a way, Alzheimer’s disease encapsulates all the imperfections of French research: no strategic oversight by a legitimate body, a preference for structures over projects, a persistent tendency to oppose "fundamental" to "applied," no anticipation of major changes in living systems, not enough epidemiology, and, let’s say it, a waning trust between research and the French people. The result is simple. Alzheimer’s disease interests French research little, which only gives more credit to those of you who have taken an interest in it. Alzheimer’s disease has been less well addressed by French research than other brain diseases, even though Alzheimer’s is the most common. I want to put an end to this abnormal situation. We must rebuild French research by uniting the immense talents it harbors. There is tremendous energy in French research, skills that many countries envy us and sometimes attract to themselves. But this energy and these skills are scattered across fragmented structures and means. I want the Alzheimer Plan to be the beginning of the reorganization of French research. I ask the commission to examine the possibility of creating a national research structure on Alzheimer’s disease. This structure, which could be a department of a large medical research organization, would aim to attract the best teams internationally, in a necessarily multidisciplinary approach. It would give ample space to epidemiology and would know how to call upon social sciences. Having the critical size, built on the principle of excellence, involving health industry players, this national research structure can help accelerate the story. It is not about creating yet another agency, in a sense a "thing" on top of everything else. It is, on the contrary, about uniting what is currently dispersed, preventing any new fragmentation of resources, being attractive, in a word, ensuring that we achieve results. We have no other choice but victory against this disease.

The patient’s journey is the third orientation defined by the commission. This journey begins with their general practitioner, and a large number of professionals accompany them afterward. The role of the general practitioner is essential to eliminate late diagnoses, regardless of age. The general practitioner is a local doctor, who knows the patient in their environment, and who can follow them over time. They make home visits. If needed, an appointment can be obtained on the same day. Attentive to the person and their family, the general practitioner is best placed to early identify individuals who may have an early-stage disease. They can refer the person to a memory consultation. They can provide support to family caregivers who, in two-thirds of cases, are depressed. They are responsible for ensuring regular follow-up for the sick person. They also play a role in preventing crisis events that accelerate the progression of the disease. Ultimately, they are the guarantor of continuity of care for Alzheimer’s patients. Their position is unique to understand and help sick individuals continuously, over 5 to 15 years. Only they can follow a chronic disabling disease like Alzheimer’s, with phases of crisis and phases of stabilization. I wish for the general practitioner’s action in favor of the sick person to be better organized. I ask, along with Roselyne, the commission to study the conditions for greater coherence between the remuneration model of the general practitioner and the follow-up of individuals with Alzheimer’s disease. Could an "Alzheimer package" be established? How can we eliminate late diagnoses with the help of the general practitioner? When the diagnosis is certain, could the follow-up of sick individuals by their general practitioner involve, at certain times, paramedical staff or social workers within the framework of a medical-social consultation?

In the same vein, could a nurse not claim, through pathways, access to more specialized professions? We have everything to gain from breaking down the barriers between fields. The social elevator must work again for everyone. I am not saying that we should align everyone towards the highest status; that would not make sense. I am saying that the best must be able to evolve, in the interest of the professions themselves and their dynamism, and in the interest of patients to maintain a high level of care. The care of Alzheimer's disease undoubtedly calls for new skills. We lack coordination skills, at the intersection of medical and social care. The coordination of all actors involved in care, particularly for the sick person at home, is a path that must be explored. Ultimately, these are the principles of the "LMD" system that I want to promote. It is probably not desirable to apply the principles of the "LMD" system indiscriminately to all health and medico-social professions. But using the advantages of the LMD wisely to promote social mobility and intermediate professions is what I intend to encourage. I hope the commission will make proposals in this regard. The Government will fully commit to implementing the measures you propose.

Finally, patients and their families often need support in terms of housing and transportation. This is an essential part of the patient's journey. We must be clear. The priority, for me, is the free choice of patients and families. In some cases, for seriously ill patients, accommodation in an institution is inevitable. Let us not deceive ourselves: there are situations where it is no longer possible to remain at home. When staying at home becomes dangerous, our duty is to protect the person. But there are those whose illness is compatible with a life organized in a familiar setting, with the appropriate help. The wish that patients express in their vast majority is to remain at home. The question is no longer whether institutional accommodation is preferable to staying at home. The question is rather whether there is a continuum of care between home and "all-institution" that allows caregivers to find the absolutely necessary moments of respite. We return to the moments of crisis in the life of the patient. Even for the moderately affected person, there can be moments of crisis. It is precisely during these crises that alternative accommodation solutions to home should take over. Is temporary accommodation, day care, sufficiently developed in France? Should we promote the creation of other types of structures in this "continuum"? Under what conditions? The transportation of the patient and their caregivers is, from this perspective, a crucial issue. Respite structures are of no use if their access is already a problem. I am convinced that all the potential of research in social sciences and research in home automation has not yet been fully exploited. We must go further in adapting housing to the needs of the sick person: the need for comfort, the need for simplicity. Other questions arise if we push the analysis further. What should be the priorities of the institutional accommodation policy? Is it to increase the number of places or to improve the quality of care for existing places, given the increasing severity of cases? And, in the more specific area of care quality, should we focus on staff, on equipment, on architecture? Has the necessary equipment for the safety and accessibility of individuals been implemented in all establishments? On all these questions, we need firm answers to act better.

I would like to conclude my intervention, and this is the fourth and final direction that the commission has submitted to me, on the theme of young patients. This is the theme that brings us together today. Young patients are emblematic. How many young patients are there in France? We do not know: perhaps around 10,000 people under the age of 60. Their situation is terrible as they are squarely in the realm of the unspeakable. It is the disease of aging par excellence that affects women and men who work and sometimes have young children. It is the shock of two life models that our society cannot accept: memory loss in the midst of active life! Caregivers clearly express the absolute drama that these individuals and their families experience: the refusal or even impossibility of diagnosis, the gradual exclusion from the world of work without being able to name the disease, and the misunderstanding that constricts and torments loved ones.

I want to extend a hand to young patients. I want those affected by early forms of Alzheimer's disease to benefit from specific measures. I want these measures to be inspired by those taken in their time for rare diseases. A national mission will be entrusted to a reference center for the benefit of young patients. This reference center will ensure the development of the diagnosis of these very early forms of the disease. It is a difficult diagnosis that must use different medical techniques. We must offer these patients immediate access to any new therapeutic options that could affect the progression of their disease and their quality of life. It is desirable, while respecting the rights of patients, to know them all in order to give them access to any test that could differentiate the various forms of the disease.

The challenge posed by young patients is that of their care. The way to alleviate their personal and family suffering is not the same as that intended for the elderly. The assessment of the progressive loss of autonomy of these individuals in the midst of family and professional activity is also organized differently. Young patients have a form of the disease that, fundamentally, has little to do with that which affects our elders. That is why I prefer to assimilate the early-onset forms of the disease to rare diseases. I therefore ask the commission to include targeted measures for young patients in the Alzheimer Plan, whether in research, care, or medico-social support.

There you go, Madam President, I want to reiterate, but is it necessary, my personal commitment to the implementation of this Alzheimer Plan. This Alzheimer's disease is a disaster for our society. But, on many issues, there is hope. A pathology of the modern world, associated with longevity, Alzheimer's disease is still at the beginning of its evolutionary cycle. It is up to us to shorten the cycle. The time will come for certain diagnoses and effective treatments. For now, we must rely on the strengths that are ours: the patients, the families, the professional caregivers, the friends, and then, as you have understood today, the entire government, mobilized. I know, people will say again, my God, what energy! Another speech! But, Ladies and Gentlemen, that is not the question. The question is to provide solutions to the problems that are those of your loved ones or that are your own. My duty as Head of State is to provide solutions, not to provide them at the end of my term to say: "My God, I would like another term because I did not have time to do everything I had planned to do." I want to work: from the first minute to the last minute.

All of us, together, stronger against the disease. Let us have confidence.

Thank you.